

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of ~~delivering an antigen to a Class I MHC receptor to induce~~ inducing immunity against ~~the an~~ an antigen in a subject having a disease associated with the presence of the antigen in the subject, which method comprises:
 - a) contacting antigen presenting cells (APCs) with filling particles with the antigen and ATP resulting in antigen- and ATP-filled particles (Ag/ATP-filled particles) under conditions permitting phagocytosis of the particles by the APCs, wherein the particles are coated with a ligand for the APC; and
 - b) ~~coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;~~
 - c) ~~incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and~~

~~d)b)~~ administering the ~~antigen-presenting cells~~ APCs (~~Ag-APCs~~) ~~of~~ resulting from step (ea) to ~~a~~ the subject ~~having the disease~~ so as to induce Class I MHC presentation and elicit cytotoxic T-lymphocytes against the antigen, thereby inducing immunity against the antigen in the subject.

2. (Previously presented) The method of claim 1, wherein the particles are type O red blood cell ghosts.
3. (Previously presented) The method of claim 1, wherein the particles are liposomes.
4. (Original) The method of claim 1, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.
5. (Previously presented) The method of claim 1, wherein the antigen presenting cells are selected from the group consisting of dendritic cells, Langerhans cells, monocytes, mononuclear phagocytes, macrophages, Kupfer cells, microglial cells, osteoclasts, and bone marrow-derived leukocytes.
6. (Original) The method of claim 1, wherein the antigen is a purified antigen.
7. (Original) The method of claim 6, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen..

8. (Previously presented) The method of claim 1, wherein the antigen is derived from a crude cell extract.
9. (Original) The method of claim 8, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.
10. (Original) The method of claim 6, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.
11. (Currently amended) The method of claim 1, wherein the Ag/ATP-filled particles further comprising ~~delivering~~ comprise at least one stimulatory cytokine ~~with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.~~
12. (Original) The method of claim 11, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.
13. (Original) The method of claim 1, wherein the immunity induced is against a bacterial or viral antigen.
14. (Previously presented) The method of claim 1, wherein the immunity induced is against an antigen present in a cancerous tumor.
15. (Previously presented) The method of claim 1, wherein the subject is afflicted with a bacterial- or a viral-mediated disease.

16. (Original) The method of claim 1, wherein the disease is cancer.

17. (Currently Amended) A method of ~~delivering an antigen to~~
~~a Class I MHC receptor to induce~~ inducing immunity
against ~~the an~~ antigen in a subject having a disease
associated with the presence of the antigen in the
subject, which method comprises:

- a) contacting antigen presenting cells (APCs)
with~~filling~~ particles with the antigen and ATP
~~resulting in~~ antigen- and ATP-filled particles
(Ag/ATP-filled particles) under conditions
permitting phagocytosis of the particles by the
APCs, wherein the particles are coated with a ligand
for the APC;
- b) ~~coating the Ag/ATP-filled particles of step (a) with~~
~~a ligand for an antigen presenting cell resulting in~~
~~a ligand-coated Ag/ATP-filled particles;~~
- c) ~~incubating the ligand-coated Ag/ATP-filled particles~~
~~of step (b) with isolated ligand-binding antigen~~
~~presenting cells (APCs) under conditions permitting~~
~~the ligand-binding APCs to bind to the ligand-coated~~
~~Ag/ATP-filled particles and APC phagolysosomes to~~
~~ingest the ligand-coated Ag/ATP-filled particles to~~
~~facilitate transfer of the ingested antigen from the~~
~~phagolysosomes into cytoplasm such that the antigen~~
~~is delivered to a Class I MHC receptor and is~~
~~expressed on the surface of the APCs (Ag-APCs);~~

db) incubating the Ag-APCs of step (ea) with lymphocytes previously removed from the subject having the disease; and

ec) administering the incubated lymphocytes ~~of resulting~~ from step (db) to the subject ~~so to induce thereby~~ inducing immunity against the antigen in the subject.

18. (Previously presented) The method of claim 17, wherein the particles are type O red blood cell ghosts.

19. (Previously presented) The method of claim 17, wherein the particles are liposomes.

20. (Original) The method of claim 17, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

21. (Previously presented) The method of claim 17, wherein the antigen presenting cells are selected from the group consisting of dendritic cells, Langerhans cells, monocytes, mononuclear phagocytes, macrophages, Kupfer cells, microglial cells, osteoclasts, and a bone marrow-derived leukocytes.

22. (Original) The method of claim 17, wherein the antigen is a purified antigen.

23. (Original) The method of claim 22, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral

antigen.

24. (Previously presented) The method of claim 17, wherein the antigen is derived from a crude cell extract.
25. (Original) The method of claim 24, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.
26. (Original) The method of claim 22, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.
27. (Currently amended) The method of claim 17, wherein the Ag/ATP-filled particles further ~~comprising~~ delivering comprise at least one stimulatory cytokine ~~with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.~~
28. (Original) The method of claim 27, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.
29. (Original) The method of claim 17, wherein the immunity induced is against a bacterial or viral antigen.
30. (Previously presented) The method of claim 17, wherein the immunity induced is against an antigen present in a cancerous tumor.

Applicants: Samuel C. Silverstein et al.
Serial No.: 09/658,698
Filed: September 8, 2000
Page 8

31. (Previously presented) The method of claim 17, wherein the subject is afflicted with a bacterial- or a viral-mediated disease.

32. (Original) The method of claim 17, wherein the disease is cancer.

33-132. (Canceled)